Canada - English - Health Canada

chiesi farmaceutici s.p.a. - lomitapide (lomitapide mesylate) - capsule - 5mg - lomitapide (lomitapide mesylate) 5mg - miscellaneous antilipemic agents

Canada - English - Health Canada

chiesi farmaceutici s.p.a. - lomitapide (lomitapide mesylate) - capsule - 10mg - lomitapide (lomitapide mesylate) 10mg - miscellaneous antilipemic agents

Canada - English - Health Canada

chiesi farmaceutici s.p.a. - lomitapide (lomitapide mesylate) - capsule - 20mg - lomitapide (lomitapide mesylate) 20mg - miscellaneous antilipemic agents

Israel - English - Ministry of Health

medison pharma ltd - lomitapide as mesylate - capsules - lomitapide as mesylate 10 mg - lomitapide - an adjunct to a low-fat diet and other lipid-lowering treatments, including ldl apheresis where available, to reduce low-density lipoprotein cholesterol (ldl-c), total cholesterol (tc), apolipoprotein b (apo b), and non-high-density lipoprotein cholesterol (non-hdl-c) in patients with homozygous familial hypercholesterolemia (hofh).

Israel - English - Ministry of Health

medison pharma ltd - lomitapide as mesylate - capsules - lomitapide as mesylate 20 mg - lomitapide - an adjunct to a low-fat diet and other lipid-lowering treatments, including ldl apheresis where available, to reduce low-density lipoprotein cholesterol (ldl-c), total cholesterol (tc), apolipoprotein b (apo b), and non-high-density lipoprotein cholesterol (non-hdl-c) in patients with homozygous familial hypercholesterolemia (hofh).

Israel - English - Ministry of Health

medison pharma ltd - lomitapide as mesylate - capsules - lomitapide as mesylate 5 mg - lomitapide - an adjunct to a low-fat diet and other lipid-lowering treatments, including ldl apheresis where available, to reduce low-density lipoprotein cholesterol (ldl-c), total cholesterol (tc), apolipoprotein b (apo b), and non-high-density lipoprotein cholesterol (non-hdl-c) in patients with homozygous familial hypercholesterolemia (hofh).

United States - English - NLM (National Library of Medicine)

amryt pharmaceuticals dac - lomitapide mesylate (unii: x4s83cp54e) (lomitapide - unii:82kub0583f) - lomitapide 5 mg - juxtapid is indicated as an adjunct to a low-fat diet and other lipid-lowering treatments, including ldl apheresis where available, to reduce low-density lipoprotein cholesterol (ldl-c), total cholesterol (tc), apolipoprotein b (apo b), and non-high-density lipoprotein cholesterol (non-hdl-c) in patients with homozygous familial hypercholesterolemia (hofh). limitations of use - the safety and effectiveness of juxtapid have not been established in patients with hypercholesterolemia who do not have hofh, including those with heterozygous familial hypercholesterolemia (hefh). - the effect of juxtapid on cardiovascular morbidity and mortality has not been determined. juxtapid is contraindicated in the following conditions: - pregnancy [see warnings and precautions (5.3) and use in specific populations (8.1)] . - concomitant administration of juxtapid with moderate or strong cyp3a4 inhibitors, as this can increase juxtapid exposure [see warnings and precautions (5.6), drug interactions (7.1), and clinical pharmac

European Union - English - EMA (European Medicines Agency)

amryt pharmaceuticals dac - lomitapide - hypercholesterolemia - lipid modifying agents - lojuxta is indicated as an adjunct to a low‑fat diet and other lipid‑lowering medicinal products with or without low-density-lipoprotein (ldl) apheresis in adult patients with homozygous familial hypercholesterolaemia (hofh). genetic confirmation of hofh should be obtained whenever possible. other forms of primary hyperlipoproteinaemia and secondary causes of hypercholesterolaemia (e.g. nephrotic syndrome, hypothyroidism) must be excluded.,

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

amryt pharma - lomitapide - capsule - 5mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

amryt pharma - lomitapide - capsule - 10mg